

Notice on the Completion of Disposal of Treasury Shares Under Restricted Stock-Linked Remuneration Program

July 24, 2019---Santen Pharmaceutical Co., Ltd. (Head Office: Osaka; Director of the Board, Chairman, CEO: Akira Kurokawa; hereinafter, the “Company”) announced that the disposal of treasury shares (hereinafter, the “disposal of shares” or the “disposal”) was completed on July 24, 2019 based on the Board of Directors meeting held on June 25, 2019, details of which are provided below. See Santen’s press release on “Notice on the Disposal of Treasury Shares Under Restricted Stock-Linked Remuneration Program” dated June 25, 2019 for more details.

Details

Outline of the disposal

(1)	Type and number of shares to be disposed	71,378 common shares
(2)	Disposal price	1,710 yen per share
(3)	Total amount of share disposal	122,056,380 yen
(4)	Recipients of allotment of shares to be disposed of, number thereof, and number of shares allotted to be disposed	3 Directors (excluding outside directors): 29,806 shares; 9 Corporate Officers: 41,572 shares
(5)	Disposal date	July 24, 2019

Contact:

Christopher Hohman

General Manager, Corporate Communications Group

E-mail: ir@santen.com Tel: +81-6-4802-9360

About Santen

As a specialized company dedicated to ophthalmology, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products, and medical devices. Santen is the market leader for prescription ophthalmic pharmaceuticals in Japan and its products now reach patients in over 60 countries. With scientific knowledge and organizational capabilities nurtured over a nearly 130-year history, Santen provides products and services to contribute to the well-being of patients, their loved ones and consequently to society. For more information, please visit Santen’s website (www.santen.com).